[go: up one dir, main page]

WO2012147842A1 - Agent favorisant une belle peau et son utilisation - Google Patents

Agent favorisant une belle peau et son utilisation Download PDF

Info

Publication number
WO2012147842A1
WO2012147842A1 PCT/JP2012/061191 JP2012061191W WO2012147842A1 WO 2012147842 A1 WO2012147842 A1 WO 2012147842A1 JP 2012061191 W JP2012061191 W JP 2012061191W WO 2012147842 A1 WO2012147842 A1 WO 2012147842A1
Authority
WO
WIPO (PCT)
Prior art keywords
skin
acid
camellia
extract
beautiful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2012/061191
Other languages
English (en)
Japanese (ja)
Inventor
勉 野崎
石原　健夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BHN Co Ltd
Original Assignee
BHN Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BHN Co Ltd filed Critical BHN Co Ltd
Priority to PH1/2013/502215A priority Critical patent/PH12013502215A1/en
Priority to KR1020137026500A priority patent/KR101840508B1/ko
Priority to CN201280020408.4A priority patent/CN103501800B/zh
Publication of WO2012147842A1 publication Critical patent/WO2012147842A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/302—Foods, ingredients or supplements having a functional effect on health having a modulating effect on age
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Definitions

  • the present invention comprises a collagen peptide and a blood flow improving agent as active ingredients, for improving skin troubles such as skin wrinkles, moisture, firmness, sagging and / or more beautiful skin
  • the present invention relates to a beautifying skin-promoting agent, an oral composition containing the beautifying skin-promoting agent, and methods for using these.
  • the skin is composed of epidermis, dermis and subcutaneous tissue.
  • the epidermis is composed of the stratum corneum, granule layer, spiny layer and basal layer, and contains many cells such as keratinocytes and melanocytes, and plays a role in preventing invasion of harmful substances and pathogens from the outside, and suppressing the transpiration of moisture. Yes.
  • the dermis unlike the epidermis, there are few cells, and it is occupied by extracellular components such as proteins produced by fibroblasts such as collagen and elastin, and mucopolysaccharides such as hyaluronic acid and chondroitin sulfate.
  • Non-Patent Document 1 Support of cells and skin tissues, water retention in cell gaps, maintenance of skin lubricity and flexibility, role of protecting skin tissues from external factors such as ultraviolet rays, dry environment, mechanical irritation and damage, microbial infection, etc.
  • the extracellular matrix components are denatured and decomposed under the influence of aging and daily ultraviolet rays, and the amount of synthesis is also reduced by the deterioration of fibroblasts.
  • Degradation of the extracellular matrix and a decrease in the amount of synthesis may cause various skin troubles such as dryness, rough skin, reduced elasticity and flexibility, decreased firmness and gloss, wrinkles, sagging and dullness.
  • skin troubles such as dryness, rough skin, reduced elasticity and flexibility, decreased firmness and gloss, wrinkles, sagging and dullness.
  • collagen accounts for about 70% of the dry weight of the skin tissue and is deeply involved in the viscoelasticity of the skin.
  • hyaluronic acid is a substance that has a great influence on the moisture retention of skin tissue, it is important to maintain and enhance collagen and hyaluronic acid in the skin tissue.
  • Patent Document 1 Gelatin and / or collagen degradation products (Patent Document 1) ), N-acetylglucosamine (patent document 2), sphingomyelin (patent document 3), genkwanin (patent document 4), oni strawberry (patent document 5) and the like have been proposed.
  • the blood flow improving agent improves the function of transporting blood to each tissue of a living body.
  • Blood plays a very important role in maintaining the functions of living tissues by supplying oxygen, nutrients, water, hormones, and the like to peripheral tissues, transporting immune cells, discharging waste products, and regulating body temperature.
  • Improve blood flow to relieve symptoms such as arteriosclerosis, hypertension, decreased immunity, alopecia, fatigue, swelling, stiff shoulders, coldness, numbness in the limbs, dark circles under the eyes and skin dullness are known.
  • substances that improve blood flow include ginkgo biloba extract, safflower extract, placenta extract, capsicum extract, capsaicin, carrot extract, assembly extract, fucoidan, vitamin E and its derivatives (such as tocopherol acetate), pantothenic acid and Its salts (calcium salt, sodium salt, etc.), glycyrrhizic acid and glycyrrhetinic acid and their salts (sodium salt, potassium salt, etc.), tahibo extract, arginine and its derivatives (arginine glutamate, etc.), nicotinic acid and its derivatives (methyl) Esters, etc.), rosemary extract, ginger extract, gingerol, gingerol, gingeron, isoflavone, vitamin B 3 , turmeric extract, grape seed, leaf, stem, etc.
  • vitamin E and its derivatives such as tocopherol acetate
  • pantothenic acid and Its salts calcium salt, sodium salt, etc.
  • An object of the present invention is to provide an oral composition for promoting skin and a method for improving skin condition and / or promoting beautiful skin.
  • the present inventors have conducted extensive studies on the relationship between various kinds of materials and beautiful skin, and as a result, the combination of a collagen peptide and one having an effect of improving blood flow is surprisingly remarkable.
  • Collagen peptide comprising at least one selected from plant extracts containing camellia seed extract, thioctic acids, resveratrols and resveratrols It was found that it is extremely effective to use in combination. Furthermore, the present inventors have found that this can be effectively used for oral compositions such as foods and drinks, feeds, pharmaceuticals, and quasi drugs, and have completed the present invention.
  • the feature of the present invention resides in a skin beautification promoter comprising a collagen peptide and a blood flow improving agent as active ingredients.
  • the collagen peptide is preferably one or more selected from the group consisting of collagen, gelatin, and hydrolysates thereof, and the hydrolyzate has a molecular weight (average molecular weight, below). The same) is preferably from about 200 to about 10,000.
  • the blood flow improving agent may be one or more selected from the group consisting of camellia seed extract, thioctic acid, resveratrol and plant extract containing resveratrol, among others. desirable.
  • the camellia seed extract contains an aqueous component obtained by extracting defatted camellia seeds with water and / or lower alcohol, and preferably contains saponins, and the saponins are particularly Camellia saponins ( More preferably, it is one or more selected from Camellia saponin) A1, Camellia saponin A2, Camellia saponin B1, Camellia saponin B2, Camellia saponin C1, and Camellia saponin C2.
  • the thioctic acids are selected from the group consisting of thioctic acid (including racemate), its reduced form, their salts, their esters, their amides, and their cyclodextrin inclusions or lipid coatings. It is desirable to be a seed or two or more.
  • resveratrol is a resveratrol monomer, or a polymer such as ⁇ -viniferin and one or more selected from the group consisting of isomers and / or glycosides thereof. It is desirable to include the extract, and the embodiment is more preferably an extract of a plant belonging to the vine family, the laceaceae or the legume family.
  • Another feature of the present invention is an oral composition for orally ingesting or administering the skin beautifying agent, and the oral composition is preferably a food or drink. Still another feature resides in a method for ingesting a collagen peptide and a blood flow improving agent orally, improving skin conditions such as dry skin, reduced elasticity, rough skin, and / or promoting beautiful skin, especially a cosmetic method.
  • the skin-beautifying agent of the present invention contains a collagen peptide and a blood flow improving agent, is excellent in stability such as quality, acts on skin cells to remarkably increase its proliferation, and skin components such as collagen and hyaluronic acid It promotes the production of and restores, maintains, and enhances components in skin tissue.
  • this action is enhanced by using at least one selected from camellia seed extract, thioctic acids, and resveratrol with a collagen peptide. This prevents and / or ameliorates skin problems such as skin dryness, roughness, loss of elasticity and flexibility, reduction in elasticity and gloss, wrinkles, sagging and dullness, and also promotes beautiful skin. Play.
  • the said skin beautification agent can be effectively used with the form of the said agent, or the form mix
  • the present invention provides a cosmetic method for orally ingesting a collagen peptide and a blood flow improving agent to improve skin conditions such as dry skin, reduced elasticity, and rough skin and / or promote beautiful skin.
  • the skin beautification promoter of the present invention is characterized by containing a collagen peptide and a blood flow improving agent as active ingredients.
  • Collagen peptides used in the skin beautification promoter of the present invention include cattle, pigs, chickens, turkeys, ostriches and other animal skins, bones, cartilage, tendons, etc., lobsters, salmon, sharks, cod, tilapia, Nile perch, carp, rockfish, It is a peptide obtained by hydrolyzing collagen, obtained by treatment of fish skin such as tuna, catfish, eel, etc., bone, cartilage, scales, etc. by conventional methods, or gelatin obtained by heat denaturation of the collagen with acid, alkali or enzyme. is there.
  • the collagen peptide in the present invention includes a collagen peptide and an extract containing the same, and these can be arbitrarily used.
  • collagen peptide obtained by hydrolyzing collagen or gelatin, and has a molecular weight of about 200 to about 10,000, more preferably about 200 to about 5,000, still more preferably about 200 to It is about 1,000.
  • the blood flow improving agent related to the skin beautifying agent of the present invention includes, for example, camellia seed extract, thioctic acid, resveratrol, plant extract containing resveratrol, ginkgo biloba extract, safflower extract Products, placenta extract, capsicum extract, capsaicin, carrot extract, assembly extract, fucoidan, vitamin E and its derivatives (such as tocopherol acetate), pantothenic acid and its salts (calcium salt, sodium salt, etc.), glycyrrhizic acid and glycyrrhetic acid Salts thereof (sodium salt, potassium salt, etc.), tahibo extract, arginine and derivatives thereof (arginine glutamate, etc.), nicotinic acid and derivatives thereof (methyl ester, etc.), rosemary extract, ginger extract, gingerol, gingerol, Zingeron, isoflavone, bitami B 3, turmeric extract, extract of such seeds
  • the present inventors have examined in further detail a blood flow improving agent that can exhibit a more powerful skin-promoting effect when used in combination with a collagen peptide.
  • an extract of camellia seeds It has been found that thioctic acids and resveratrols or plant extracts containing them are extremely effective. That is, the desirable skin beautification promoter of the present invention is selected from the group consisting of the aforementioned collagen peptide and a plant extract containing camellia seed extract having a blood flow improving effect, thioctic acids, resveratrols and resveratrols. It contains one or two or more selected as active ingredients.
  • the camellia refers to camellia japonica belonging to the camellia section of the genus Theaceae, Camellia, and examples thereof include C. japonica var. Japonica, (C. japonica var. Macrocarpa), C. japonica subsp. Hozanensis, C. hongkongenesis, C. reticulata, C. isluen pi. pterardii var. pitardii) and Yunnan species (C.
  • Camellia japonica and the like may be mentioned Yakushimatsubaki (apples Camellia same kind), and the like. What is necessary is just to utilize suitably these camellia which are growing naturally in the Japanese archipelago, the Korean peninsula, the Shandong peninsula of China, etc.
  • the aforementioned camellia fruits and / or seeds are squeezed, a hydrophobic organic solvent such as hexane or heptane, or a liquefied gas such as liquefied carbon dioxide or liquefied propane is used. It is desirable to use a defatted material (hereinafter sometimes referred to as defatted soot), which is a residue obtained by extracting and separating oil by a conventional method, for example, a supercritical extraction treatment.
  • defatted soot a defatted material
  • camellia fruits and / or seeds may be either early-ripening fruits or mature fruits, and these seeds may be used, but when mature fruits or seeds thereof are used, the yield of defatted products and / or active ingredients is high. It is desirable. More preferably seeds are used. In a preferred embodiment, seeds obtained from mature fruits are dried for about 1 to 2 weeks in the sun.
  • the active component of the camellia seed extract according to the present invention is desirably an aqueous component.
  • the aqueous component can be produced by any method using the defatted soy sauce as a raw material, but it is preferable to perform extraction using water and / or a lower alcohol.
  • the lower alcohol has a tendency to extract oily substances in the defatted soot as the carbon number increases. Therefore, those having a carbon number of up to about 5 are desirable.
  • the water content in the case of propanol is about 20 to about 50% by mass, and the water content in the case of butanol is about 40 to about 70% by mass.
  • Desirable extraction solvents are water, methanol and ethanol, and water-containing alcohols thereof, more preferably water or water-containing methanol or water-containing ethanol having a water content of 50% by mass or more, and more preferably water.
  • the extraction solvent is added about 1 to about 30 times by mass with respect to 1 part by weight of the defatted soot, and at about normal pressure or about 1 to about 5 atm. After stirring and mixing for 10 minutes to about 3 hours as necessary, the mixture is cooled to room temperature and filtered, and the filtrate is concentrated and dried by an appropriate means such as drying under reduced pressure, spray drying or freeze drying. This dried product may be appropriately pulverized. In this way, a light yellow to yellow-red solid that is a water-soluble component contained in camellia seeds according to the present invention can be obtained.
  • the extraction residue once extracted is similarly subjected to repeated extraction treatment, or is performed at about 100 to about 130 ° C.
  • the extract can be further subjected to known means such as solvent fractionation, fractionation with a column packed with an adsorbent such as ion exchange resin, silica gel, activated alumina, and fractionation by liquid chromatography. It can also be used to concentrate and purify the active ingredient.
  • This water-soluble component includes saponin, tannin and the like.
  • thioctic acids are not particularly limited, and natural product extracts of organs such as livers of cattle and pigs, for example, chemicals starting from ethylene and adipic acid esters are used. It may be collected and produced by a known method such as a synthetic product. Since thioctic acid has an asymmetric carbon, there are enantiomers ((R) -enantiomer and (S) -enantiomer) having different optical properties. However, thioctic acid according to the present invention can be any one of these. It may be a mixture in an arbitrary ratio, or may be a racemate (racemic mixture or racemate) ((R), (S) -thioctic acid). In the implementation at the industrial production level, it is convenient to use a commercially available racemate that is inexpensive and easily available. Use of a racemate is desirable because it tends to exert the desired effect of the present invention more strongly.
  • the thioctic acids used in the skin beautifying agent of the present invention can appropriately utilize various derivatives in addition to the above thioctic acid, such as thioctic acid, its reduced form, their salts, their esters, their amides, and It is desirable that they be one or more selected from the group consisting of those cyclodextrin inclusions.
  • Specific examples of the reduced form of thioctic acid include dihydrothioctic acid, dihydrolipoic acid, 6,8-dimercapto-octanoic acid, (R), (S) -dihydrothioctic acid and the like.
  • Salts include (R) -thioctic acid, (S) -thioctic acid, (R), (S) -thioctic acid, (R) -dihydrothioctic acid, (S) -dihydrothioctic acid, (R), ( Examples thereof include potassium salts such as S) -dihydrothioctic acid, sodium salts, calcium salts, and magnesium salts.
  • Esters include (R) -thioctic acid, (S) -thioctic acid, (R), (S) -thioctic acid, (R) -dihydrothioctic acid, (S) -dihydrothioctic acid, (R), ( S) -dihydrothioctic acid and the like and partial alcohols or complete esters or glycerides (monoglycerides, monomers such as ethylene glycol, propylene glycol, butanediol, neopentyl glycol, glycerol, erythritol, polyglycerol, etc.) And monoesters with higher alcohols having 10 to 22 carbon atoms (decanol, lauryl alcohol, myristyl alcohol, cetanol, stearyl alcohol, isostearyl alcohol, behenyl alcohol, etc.).
  • Amides include (R) -thioctic acid, (S) -thioctic acid, (R), (S) -thioctic acid, (R) -dihydrothioctic acid, (S) -dihydrothioctic acid, (R), ( Examples include amides such as S) -dihydrothioctic acid.
  • Examples of the inclusion product of cyclodextrin include an inclusion product of ⁇ -, ⁇ -, ⁇ -, or ⁇ -cyclodextrin and the thioctic acid or its derivative. In addition, this invention is not limited by these illustrations.
  • thioctic acids one or more crystals selected from the group consisting of the above thioctic acid, its reduced form, their salts, their esters, their amides, and their cyclodextrin inclusion products.
  • powders and / or particles whose outer surface is coated with lipids are included, and this embodiment is practical for suppressing thermal alteration (decomposition, polymerization, discoloration, etc.), moisture absorption or oxidative modification of thioctic acids. In particular, it is more desirable.
  • the lipids that coat the outer surface of the thioctic acid crystals, powder, and / or particles may be acceptable as long as they are acceptable in the industrial field in which the present invention is used, such as general edible oils or industrial fats and oils, Fatty acid glycerides, fatty acids, fatty acid esters, fatty acid amides, higher alcohols, waxes, sterols, glycolipids, phospholipids and the like can be used alone or in combination. Of these, lipids having a melting point of about 30 ° C. or higher are preferable in consideration of coating workability and physical properties of the coating (stability, solidification, fluidity, meltability, solubility, etc.).
  • More preferred forms are lipids having a melting point of about 40 ° C. to about 70 ° C., and still more preferred forms are lipids having a melting point of about 40 ° C. to about 60 ° C.
  • the melting point is less than about 30 ° C., the coating may not be able to maintain a solid state during use, and may form a lump or impair flowability.
  • the temperature exceeds about 70 ° C., the thioctic acids themselves may be deteriorated due to the influence of heat treatment or mechanical energy in producing the inhibitor or composition according to the present invention.
  • lipids include soybean oil, rapeseed oil, corn oil, sunflower oil, cottonseed oil, wheat germ oil, rice oil, sesame oil, olive oil, safflower oil, palm oil, palm kernel oil, coconut oil, linseed oil , Vegetable oils such as peanut oil, animal fats such as beef tallow, lard, fish oil, processed oils and fats that have been subjected to one or more of such treatments as fractionation, transesterification, decolorization, deodorization, etc., partially or completely Various hydrogenated hydrogenated oils, saturated fatty acids having 2 to 22 carbon atoms (acetic acid, butyric acid, caproic acid, caprylic acid, capric acid, lauric acid, myristic acid, pentadecanoic acid, palmitic acid, stearic acid, 12-hydroxystearic acid , Isostearic acid, arachidic acid, behenic acid, etc.) or unsaturated fatty acids (palmitoleic acid,
  • Oil-derived wax wax derived from minerals such as montan wax, ozokerite, polyethylene wax, synthetic waxes such as esters of the above fatty acids and higher alcohols, sterols (animal cholesterol, plant campesterol, stigma) Sterol, sitosterol, etc., fungus-derived ergosterol, derivatives thereof, phospholipids (animal and plant-derived lecithin, phosphatidylcholine, phosphatidylethanolamine, phosphatidylino) Thor, phosphatidylserine, phosphatidic acid, sphingomyelin, etc.), glycolipids (monoglucosyl diglyceride, monogalactosyl diglyceride, diglucosyl monoglyceride, digalactosyl monoglyceride, monoglucosyl diglyceride, digalactosyl diglyceride, sucrose fatty acid ester, etc.) Can do. In addition, this invention is not limited at all by these
  • any one or a mixture of two or more of the above-mentioned various lipids can be used.
  • Preferred types of lipids include the above-mentioned edible oils or industrial fats, fatty acid glycerides, fatty acid esters and Waxes, more preferably edible fats and oils and fatty acid glycerides, and these and one or more selected from fatty acids, higher alcohols, sterols, glycolipids or phospholipids
  • the combination is a more desirable embodiment from the viewpoint of adjusting the melting point of the coated lipid, reinforcing the coating film, and the like.
  • a known method can be used. That is, ball mill, flash blender (powder granule mixer), V-type mixer, high-speed mixer, high-speed paddle mixer, heat-melt mixer, ultrasonic super-humidified liquid-type mixer, tumbler mixer, pressure extruder, etc.
  • flash blender powder granule mixer
  • V-type mixer high-speed mixer
  • high-speed paddle mixer high-speed paddle mixer
  • heat-melt mixer ultrasonic super-humidified liquid-type mixer
  • tumbler mixer pressure extruder, etc.
  • the thioctic acid crystals, powder and / or particles and the heated and melted lipids are uniformly mixed, cooled and solidified, and then pulverized.
  • a method of coating by spraying or dripping the lipids which have been formed, and stirring and mixing the thioctic acids of the above-mentioned form and particulate lipids at high speed, and bringing them into contact or colliding with each other, thereby producing crystals, powders and / or thioctic acids.
  • a method in which particulate lipids are uniformly attached to the entire surface of the particle and coated is possible.
  • thioctic acid crystals, powders and / or particles and particulate lipids having a specific melting point or higher are mixed with high-speed stirring, and both are brought into contact with or collided with each other to obtain the thioctic acid of the above form.
  • a method of uniformly coating particulate lipids on the entire surface of acids is desirable.
  • the ratio of thioctic acid crystals, powders and / or particles to lipids, thioctic acid crystals, powder and particle shapes and sizes, lipid types and melting points, coating film thickness and
  • about 0.05 to about 10 parts by mass, preferably about 0.1 parts by weight of lipids are generally added to 1 part by mass of crystals, powders and / or particles of thioctic acids.
  • About 5 parts by mass If the lipid is less than about 0.05 parts by mass, the coating state is not sufficient and the desired effect is hardly exhibited. Conversely, if it exceeds about 10 parts by mass, the thioctic acid content in the coating is low, In the scene where it is used, the blending rate and the like are limited, and the practical value may be impaired.
  • the above-described coating of thioctic acids with lipids is more preferably an embodiment in which the outer surface is further coated with a hydrophilic substance regardless of whether or not this is applied to an aqueous composition such as a beverage. More desirable.
  • the hydrophilic substance means a substance that further coats the outer surface of the coating with lipids and has a coating film-forming ability having an affinity with an aqueous substance.
  • polysaccharides xanthan gum, guar gum, Tamarind seed gum, psyllium seed gum
  • starch and modified starch yeast cell wall components, glucan, mannan, shellac, sodium alginate, gelatin, carrageenan, pullulan, carboxymethylcellulose, soy protein, whey protein, zein, etc.
  • it is one or more selected from the group consisting of polysaccharides, starch, yeast cell wall components, shellac, gelatin, soybean protein, zein and mannan, and more preferably from yeast cell wall components, shellac and gelatin. 1 type or 2 types or more chosen from the group which consists of.
  • a method according to the above-described lipid coating method may be employed. That is, the hydrophilic substance is appropriately dissolved in water, ethanol, or other solvent to form a liquid, and this is attached to the outer surface of thioctic acid previously coated with lipids and dried to coat the hydrophilic substance. A film can be formed.
  • Such a coating becomes a double-coated structure having a hydrophilic substance as the outermost layer, and when this is used for foods, drinks, feeds, cosmetics, pharmaceuticals, etc., the affinity with aqueous raw materials and ingredients increases, It becomes easy to prepare a homogeneous composition with thioctic acids having low solubility.
  • these include Garcinia camphor peel, red pepper rhizome, guava leaf and extracts thereof (water And / or one or two selected from the group consisting of an extract with a hydrophilic organic solvent (e.g., a lower monohydric alcohol such as ethanol, acetone, its fraction, a solvent fraction or a purified product), and carnitine.
  • a hydrophilic organic solvent e.g., a lower monohydric alcohol such as ethanol, acetone, its fraction, a solvent fraction or a purified product
  • thioctic acids having excellent stability that can further suppress thermal and / or oxidative denaturation and deterioration of thioctic acids by coexisting coexistence with red pepper rhizome extract and carnitine, most preferably carnitine.
  • Such an embodiment of thioctic acid is more desirable in the present invention because a containing coating is obtained.
  • the combination raw materials are mixed in a coating in which lipids are coated on thioctic acid crystals, powder and / or particles, (ii) (Iii) Disperse a part of the combination raw material in the thioctic acid crystals, powder and / or particles, and coat the lipid with a mixture of the thioctic acid crystals, powder and / or particles and the combination raw material. (Iv) a solution, dispersion or emulsion containing the thioctic acid crystals, powders and / or particles coated with lipids, and the combined raw material and the hydrophilic substance.
  • the aspects (i) and (iv) exhibit the desired effects of the present invention, the production is simple, and the handling workability of the coating is good, but the aspects (i) and (iii) are desirable. It is easy to express the effect of.
  • the mixing ratio of the coating material obtained by coating the crystals, powders and / or particles of thioctic acid with lipids or lipids and a hydrophilic substance, and the combination raw material is used in combination with 1 part by mass of the coating material.
  • the raw material is about 0.01 to about 10 parts by weight, more preferably about 0.1 to about 1 part by weight.
  • the amount is less than about 0.01 parts by mass, the desired effect cannot be improved by mixing the combined raw materials.
  • the amount exceeds about 10 parts by mass the thiocte in the coating and further in the composition using the same. The acid content is lowered, and as a result, the thioctic acid content in various products containing the thioctic acid-containing composition is limited, and the desired effect of thioctic acid itself cannot be expected in the product stage.
  • the origin and type of resveratrol according to the present invention is not particularly limited, and may be a well-known organic chemical method, or one collected / manufactured using a microorganism, yeast, etc. It is desirable that it is obtained by extraction from parts such as pericarp, stem, leaf, vine, shoot, seed, flower, fruit, etc.
  • More desirable plants as the origin of resveratrols according to the present invention are grapevine genus plants, and the varieties thereof are not particularly limited.
  • the resveratrols according to the present invention can be produced by an arbitrary method, but the above-exemplified grape stems, vines, shoots or flowers themselves, or those obtained by drying, chopping and pulverizing them. These are immersed in a solvent for a certain period of time, or are brought into contact with an extraction solvent that is heated to reflux to obtain an extract, an extract obtained by removing the solvent from the extract, silica gel, magnesium silicate in the extract , Ion-exchange resin, activated alumina, cellulose, purified products that have been subjected to purification treatment such as column chromatography using an adsorbent such as activated carbon and solvent fractionation, and those that have been pulverized by methods such as freeze-drying and spray-drying But you can.
  • hydrophilic organic solvents lower monohydric alcohols such as methanol, ethanol, propanol and isopropanol, polyhydric alcohols such as propylene glycol, 1,3-butanediol and glycerin, acetone, methyl ethyl ketone, ether, petroleum ether, ethyl acetate and These hydrates and mixtures can be exemplified.
  • the water content of the hydrated product is, for example, about 1 to about 99% by mass in the case of ethanol, more preferably about 50% by mass or less, and about 1 to about 50% by mass in the case of acetone, more preferably about 10%.
  • ethyl acetate about 80 to about 99% by weight, more preferably about 85 to about 95% by weight. Outside these ranges, the desired effect of the present invention is reduced or the yield of the extract is reduced.
  • Resveratrols according to the present invention include t-resveratrol (resveratrol monomer), polymers such as ⁇ -viniferin (dimer), Miyabenol C (trimer), and These isomers and / or stilbene compounds such as glycosides are targeted.
  • the extract obtained from the plant may contain quercetin, ellagitannin, ellagic acid, minerals (for example, potassium, calcium, phosphorus, magnesium) and vitamins as the main active ingredients. .
  • the content of the blood flow improving agent used in combination with the collagen peptide is about 0.01 to about 50% by mass, preferably about 0.1 to about 20% by mass of the total of the agent. More desirably, the amount is about 0.5 to about 10% by mass. When the amount is less than about 0.01% by mass, the effect of the combined use is small. On the other hand, when the amount exceeds about 50% by mass, a further desired effect cannot be expected.
  • the blood flow improving agent can be arbitrarily used alone or in combination with the above-mentioned known substances and extracts, but desirable ones include camellia seed extract, thioctic acids, resveratrols and resveratrols.
  • Camellia seed extract, thioctic acid, resveratrol, and the ratio (mass basis) when using two or more kinds of plant extracts containing resveratrol in general are camellia seed extract / thioctic acid 20/80 to 30/70, more preferably 60/40 to 40/60, and camellia seed extract / resveratrol is 99/1 to 30/70, more preferably 80/20 to 50/50
  • the thioctic acid / resveratrol is 99/1 to 30/70, more preferably 80/20 to 50/50, and the camellia seed extract / thioctic acid / resveratrol is used for each blood.
  • the ratio of the flow improver is about 1% by mass or more, more preferably about 10% by mass or more, based on the whole skin beautifying agent.
  • the content may be set in consideration of the content of resveratrol in the extract.
  • the aforementioned skin beautification promoter is one or two selected from the group consisting of collagen peptides and blood flow improving agents, especially camellia seed extract, thioctic acids, resveratrols and plant extracts containing resveratrols.
  • the combined use with the above as an active ingredient as it is, that is, in the form of powder, solid, paste or liquid consisting only of the active ingredient, this is food and drink, pharmaceuticals, quasi drugs, It can be used for applications such as feed.
  • the skin-beautifying agent of the present invention can also be used as an oral composition by appropriately combining known additives for the above-mentioned uses for which it can be used and containing them in a conventional manner.
  • known additives may be those usually used for ingestion, for example, excipients, binders, disintegrants, lubricants, wetting agents, fluidizing agents, preservatives, surfactants.
  • Additives such as stabilizers, diluents, solubilizers, tonicity agents, bactericides, preservatives, flavoring agents, flavoring agents, coloring agents, and fragrances can be used.
  • the skin beautifying agent of the present invention can also be used as a part of a blended raw material of various products in food and drink, pharmaceuticals, quasi drugs, feeds, and other industrial fields. In particular, it is preferably a product for beauty and the like.
  • the skin beautifying agent of the present invention When used in combination with known additives to form an oral composition, it can be made into oral preparations such as powders, granules, tablets, capsules, and liquids. It is.
  • the content of the active ingredient in such an oral composition is difficult to define uniformly depending on the type and content of the raw materials used together, but is generally about 0.1 to 100% by mass, more preferably about 10 to about 100% by mass. %. When the content is less than about 0.1% by mass, the desired effect of the present invention is not recognized.
  • the skin beautification promoter of the present invention is used in a method of taking or administering it orally.
  • the preferred intake or dosage of the oral composition of the present invention is about 100 mg to about 100,000 mg per day for a human adult (body weight 50 kg) based on the active ingredient contained in the agent. It is desirably about 500 mg to about 10,000 mg, more desirably about 1,000 mg to about 5,000 mg.
  • the skin-beautifying agent of the present invention can be used as a part of a blended raw material of known products such as foods and drinks, pharmaceuticals, quasi drugs, and feeds. Examples of practical products are described below, but the present invention is not limited to these exemplifications.
  • foods and beverages include beverages such as vegetable juice, fruit juice drinks, soft drinks and teas; cake premix products, breads, cakes, cookies, chocolates, candy, gummies, gums and other sweets; miso, soy sauce, sauces , Mayonnaise, grilled meat sauce, noodle soup, etc .; noodles such as instant noodles, udon, soba noodles, spaghetti, etc .; processed meat and fish products such as ham and sausage; Dairy products in the form of solid, liquid or liquid; sprinkles, hamburger, croquettes, boiled potatoes, jam, soup, jelly, pudding, dressing, vegetable cream, margarine, etc.
  • Pharmaceutical, tablet, soft capsule, hard capsule, paste or liquid food supplement, food for specified health use, machine Sex food mention may be made of health food products, the concentrated liquid diet and dysphagia for food diet and the like.
  • the skin beautification promoter of the present invention and known raw materials may be used, or a part of the known raw materials may be replaced with the skin beautification promoter of the present invention and manufactured by conventional methods.
  • the skin-beautifying agent of the present invention may be added to excipients such as glucose, glucose, dextrin, lactose, starch or processed products thereof, cellulose powder, vitamins, minerals, fats and oils of animals, plants, and seafood as needed.
  • White including proteins derived from animals and plants and yeasts, hydrolysates thereof), carbohydrates, pigments, fragrances, antioxidants, surfactants, other edible additives, powders and extracts containing various nutritional functional ingredients, etc.
  • the pharmaceuticals and quasi-drugs using the skin beautification agent of the present invention appropriately add known excipients and additives that are pharmaceutically acceptable within the scope of the present invention to the oral skin beautification promoter.
  • These can be processed into conventional preparations such as tablets, capsules, granules, powders, and liquids. This is orally administered and applied for the prevention or treatment of dryness, loss of elasticity, rough skin and the like.
  • the content and intake of the skin beautifying agent of the present invention contained in these pharmaceuticals and quasi drugs are based on the above-mentioned oral composition.
  • the skin beautifying agent of the present invention in order to apply the skin beautifying agent of the present invention to pet food and livestock feed, as in the case of the foods and drinks, it is blended into various known feeds and drinking water, or tablets together with known raw materials and additives.
  • the content and intake of the skin beautifying agent of the present invention in these feeds are almost the same as in the case of the aforementioned oral composition.
  • Production Example 4 (camellia seed extract (2)) 2 kg of water-containing ethanol (water content 35%) was added to 1 kg of the defatted product obtained in the same manner as in Production Example 3, and the mixture was heated to reflux at 80 ° C. for 1 hour, cooled to room temperature, and filtered to separate the filtrate. To this filtration residue, 2 L of water-containing ethanol (water content 35%) was added again and heated in the same manner. After cooling, the filtrate was collected by filtration. Both filtrates were combined, concentrated under reduced pressure, freeze-dried and pulverized to obtain 12.1 g of a powder (sample 4) containing a water-soluble component. The powder was analyzed by HPLC in the same manner as in Production Example 3. As a result, it contained 8.3% Camellia saponin B2, 5.9% Camellia saponin C2, and 2.6% Kaempferol, which is a flavonol.
  • Production Example 5 (lipid coating of thioctic acid) 200 g of thioctic acid in crystalline powder (manufactured by Altzchem, Germany, trade name: ALIPURE (registered trademark), racemic), rapeseed hydrogenated oil (manufactured by Kawaken Fine Chemical Co., Ltd., melting point: 67 ° C., flakes) was mixed well and dispersed uniformly, and then cooled and solidified at room temperature. Next, the solidified product was pulverized with a high-speed mixer, and sieved with 100 mesh (Tyler mesh; the same applies hereinafter) to obtain a thioctic acid lipid coating (sample 5) having a particle size of 150 ⁇ m or less.
  • ALIPURE registered trademark
  • rapeseed hydrogenated oil manufactured by Kawaken Fine Chemical Co., Ltd., melting point: 67 ° C., flakes
  • Test example 1 blood flow improving effect 40 subjects (24-65 years old, 20 men, 20 women) who agreed to participate in the study described below were divided into 5 groups per group and blood flow was measured by the double blind method. A test was conducted. First, the subject entered a room of constant temperature and humidity controlled at a temperature of 24 ⁇ 2 ° C. and a humidity of 50 ⁇ 10%, and was allowed to stand quietly for 10 minutes. Thereafter, the blood flow in the back of the hand before taking the test sample was measured using a laser Doppler (Periscan PIMII, manufactured by Perimed).
  • Periscan PIMII manufactured by Perimed
  • test sample was the above camellia seed extract (sample 3, sample 4), commercially available thioctic acid, thioctic acid lipid coating (sample 5), resveratrol extract (sample 7), commercially available ginkgo biloba extract.
  • Product manufactured by BN Co., Ltd.
  • carrot extract manufactured by Maruzen Pharmaceutical Co., Ltd.
  • Test Example 2 The effect on the proliferation of dermal fibroblasts was examined by the following method. That is, normal human adult dermal fibroblasts (manufactured by Kurabo Industries Co., Ltd., NHDF (NB), hereinafter simply referred to as cells) were used with 10% fetal bovine serum (Daiichi Chemical Co., Ltd.) using Petri dishes ( ⁇ 10 cm). 2 ⁇ 10 5 cells were seeded on D-MEM medium (manufactured) supplemented (Sigma, low glucose) and cultured for 4 days until it became sub-confluent (approximately 80% density).
  • D-MEM medium manufactured
  • the medium is removed, and the cells are washed twice with 5 mL of PBS and further with 5 mL of 0.02% EDTA solution, and then the cells are recovered using 5 mL of 0.25% trypsin solution (manufactured by Nacalai Tesque). After centrifugation (4 ° C., 1,000 rpm, 5 minutes), the supernatant was removed, and the cells were washed twice with PBS to obtain cells. These cells were repeatedly cultured under the above conditions and subcultured.
  • the subcultured cells were treated with a low serum medium for human skin fibroblast proliferation (Kurabo Co., Ltd., skin fibroblasts). 1 ⁇ 10 4 cells / well were seeded in 500 mL of basal medium (106S) supplemented with 10 mL of low serum growth additive (LSGS) and cultured for 24 hours. Subsequently, the medium was removed, and the culture was further continued for 48 hours in the low serum medium for human skin fibroblast proliferation to which each sample was added so that the final concentration was 5, 10 or 20 ⁇ g / mL.
  • a low serum medium for human skin fibroblast proliferation Kerabo Co., Ltd., skin fibroblasts
  • MTT solution PBS in which thiazolyl blue tetrazolium bromide (manufactured by Sigma, reagent) was dissolved
  • MTT solution PBS in which thiazolyl blue tetrazolium bromide (manufactured by Sigma, reagent) was dissolved
  • formazan solution (25% (v / v) 0.45 M acetate buffer (pH 4.5), 25% (v / v) N, N-dimethylformamide, 10% ( w / v) Contains sodium n-dodecyl sulfate, pH 4.5) was added and stirred. After standing overnight at room temperature, the absorbance at 590 nm was measured to evaluate the degree of cell proliferation.
  • the D-MEM medium and the low serum medium for human dermal fibroblast proliferation were supplemented with penicillin (final concentration 100 IU / mL) and streptomycin (final concentration 0.1 mg / mL). All were carried out in a CO 2 incubator (37 ° C., 5% CO 2 intensified gas phase).
  • the test samples were the collagen peptide (sample 1, sample 2), camellia seed extract (sample 3, sample 4), commercially available thioctic acid, thioctic acid lipid coating (sample 5), and cyclodextrin thioctoate.
  • sample 6 resveratrol extract
  • sample 7 commercially available ginkgo biloba leaf extract (manufactured by BN Co., Ltd.), carrot extract (manufactured by Maruzen Pharmaceutical Co., Ltd.) and sample 1 or sample 2 and each sample And combined use.
  • Table 2 The results are shown in Table 2, Table 3 and Table 4.
  • the numerical values are shown as relative values when the value of the control test (when no sample is added) carried out at the same time is taken as 100.
  • samples 1 and 2 were added to the medium so that final concentrations were 50 and 100 ⁇ g / mL, and other samples were final concentrations of 5 and 10 ⁇ g / mL.
  • Sample 1 and Sample 2 were 50 ⁇ g / mL, and the other samples were added to the medium by 5 ⁇ g / mL. From the data in Table 2, it was recognized that each sample had a weak effect of growing dermal fibroblasts at each addition concentration.
  • Test Example 3 (Beautiful skin test in humans) 60 volunteer females (35 to 55 years old, average age: 48.6 years old) with reduced skin elasticity and water content who had consented to participate in the study described below, They were divided into names, and each group received each sample and continued for 6 weeks. Before and after ingesting the sample, the skin elasticity is measured using a skin viscoelasticity measuring apparatus (Germany, Courtage + Khazaka, product name: CUTOMETER MPA580 (R)), and moisture of a certain part of the face is measured. The relative moisture value was measured using an apparatus (Corneometer (R) CM825).
  • the results are shown in Table 5.
  • the skin elasticity and water content before and after ingestion of the sample showed some improvement in the ingestion of each sample other than Ginkgo biloba extract compared to before ingestion. There was no big difference.
  • the samples 1 are combined with each other, the skin elasticity and water content are clearly improved, and the combination of the collagen peptide according to the present invention and the blood flow improving agent, particularly camellia extract, thioctic acids, resveratrol. It has been clarified that when used in combination with a kind, it has an effect of remarkably accelerating skin beautification.
  • Prototype example 1 (soft capsule) Sample 1 and Sample 3 (mixing ratio: 10/1), Sample 1 and Sample 7 (mixing ratio: 10/1), Sample 1 and thioctic acid (mixing ratio: 10/1), Sample 1 and Sample 3 and One of Sample 7 and thioctic acid (mixing ratio: 10/1/1/1): 200 parts, Beeswax: 40 parts and evening primrose oil (Efamol, UK): 50 parts are added and mixed by heating. After homogenization, the mixture was applied to a capsule filling machine, and a gelatin-coated soft capsule preparation having an inner volume of 250 mg per one grain was prepared by a conventional method. This capsule preparation can be used as an orally ingestible dietary supplement, pharmaceutical product or animal feed.
  • Prototype 2 (hard capsule) Sample 1 and Sample 3 (mixing ratio: 10/1), Sample 1 and Sample 4 and Sample 6 (mixing ratio: 10/3/1), Sample 1, Sample 4 and Sample 7 (mixing ratio: 10/1/1) ), Sample 1 and Sample 4 and Sample 5 and Sample 7 (mixing ratio: 10/2/1/1) were supplied to a capsule filling machine, and gelatin with an internal volume of 200 mg per grain was prepared by a conventional method.
  • a coated hard capsule formulation was prototyped. This capsule preparation can be used as an orally ingestible dietary supplement, pharmaceutical product or animal feed.
  • Prototype Example 3 (Beverage) Sample 1 and sample 3 (mixing ratio: 10/1), sample 1 and sample 7 (mixing ratio: 10/1), sample 1 and thioctic acid (mixing ratio: 10/1) each in 100 mL of commercially available energy drink , 000 mg was added and mixed thoroughly to make a beverage. Even when this was stored in a refrigerator for 6 months, no abnormalities or discomfort was observed in the appearance and flavor.
  • This product can be used as a beverage or drink for improving skin conditions such as dryness, reduced elasticity, and rough skin and / or promoting beautiful skin.
  • the skin-beautifying agent comprising a combination of the collagen peptide of the present invention and one or more selected from the three specific blood flow-improving agents as an active ingredient is taken or administered orally.
  • the skin-beautifying agent comprising a combination of the collagen peptide of the present invention and one or more selected from the three specific blood flow-improving agents as an active ingredient is taken or administered orally.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Polymers & Plastics (AREA)
  • Dermatology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Medical Informatics (AREA)
  • Birds (AREA)
  • Molecular Biology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Toxicology (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne un agent favorisant une belle peau afin d'améliorer des problèmes cutanés tels qu'une peau sèche, une perte d'élasticité et une peau gercée et/ou de favoriser une belle peau ; une composition orale favorisant une belle peau contenant l'agent favorisant une belle peau ; et une méthode d'embellissement pour améliorer un trouble cutané et/ou favoriser une belle peau. L'invention concerne un agent favorisant une belle peau contenant en tant que principe actif, un ou une association de deux types ou plus choisis dans le groupe constitué de peptides collagéniques et d'agents activateurs de la circulation sanguine ; notamment un extrait de graines de camélia, des acides thioctiques, des resvératrols et des extraits végétaux contenant des resvératrols, ainsi qu'une composition orale contenant l'agent favorisant une belle peau, et une méthode de prise orale de l'agent favorisant une belle peau ou de la composition.
PCT/JP2012/061191 2011-04-28 2012-04-26 Agent favorisant une belle peau et son utilisation Ceased WO2012147842A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PH1/2013/502215A PH12013502215A1 (en) 2011-04-28 2012-04-26 Beautiful-skin-promoting agent and use thereof
KR1020137026500A KR101840508B1 (ko) 2011-04-28 2012-04-26 피부 미용 촉진제 및 그의 이용
CN201280020408.4A CN103501800B (zh) 2011-04-28 2012-04-26 美肌促进剂及其利用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011-114156 2011-04-28
JP2011114156 2011-04-28

Publications (1)

Publication Number Publication Date
WO2012147842A1 true WO2012147842A1 (fr) 2012-11-01

Family

ID=47072357

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2012/061191 Ceased WO2012147842A1 (fr) 2011-04-28 2012-04-26 Agent favorisant une belle peau et son utilisation

Country Status (6)

Country Link
JP (1) JP6205616B2 (fr)
KR (1) KR101840508B1 (fr)
CN (2) CN103501800B (fr)
PH (1) PH12013502215A1 (fr)
TW (1) TWI436774B (fr)
WO (1) WO2012147842A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10226422B2 (en) 2013-01-23 2019-03-12 Bottled Science Limited Skin enhancing beverage composition

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6026257B2 (ja) * 2012-12-11 2016-11-16 花王株式会社 セラミド産生促進剤
JP6022333B2 (ja) * 2012-12-11 2016-11-09 花王株式会社 セラミド産生促進剤
US10722436B2 (en) 2015-08-10 2020-07-28 Mary Kay Inc. Topical compositions
KR101853927B1 (ko) 2016-08-12 2018-05-02 주식회사 제이 피부 각질 제거, 가려움증 개선, 및 두피 비듬 개선 효과가 우수한 연어 비늘의 효소 가수 분해물을 포함하는 화장료 조성물
KR102094061B1 (ko) 2017-09-18 2020-03-26 진명종 금 콜로이드를 이용한 주름 개선 및 노화 방지용 화장품 조성물 제조방법
KR101961152B1 (ko) * 2017-11-15 2019-03-25 주식회사 프롬바이오 양태반 분말과 식물의 복합물을 함유하는 피부 미백용, 피부 보습용 또는 피부주름 개선용 식품 또는 화장료 조성물
CN108719215A (zh) * 2018-03-28 2018-11-02 宜州市壮之都丝绸家纺有限公司 一种蚕的高产养殖方法
US20210252098A1 (en) 2018-06-29 2021-08-19 House Wellness Foods Corporation Composition for Improving Vascular Endothelial Function or Improving Blood Flow in Peripheral Blood Vessels
KR20210047425A (ko) 2019-10-21 2021-04-30 코스맥스 주식회사 피부 개선용 화장료 조성물
KR20230096601A (ko) 2021-12-23 2023-06-30 주식회사 앤나코스메틱 금 입자를 함유하고 색소침착 및 주름 개선에 효과있는 세럼형 화장품 조성물
TWI824585B (zh) * 2022-06-27 2023-12-01 孟鄉生化科技股份有限公司 高分子聚合膜
KR102844118B1 (ko) 2023-10-19 2025-08-08 주식회사 비네이처바이오랩 식물 연화체의 제조방법

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07206675A (ja) * 1993-10-11 1995-08-08 Asta Medica Ag 血行変化の治療薬
JP2004123637A (ja) * 2002-10-04 2004-04-22 Ichimaru Pharcos Co Ltd ヒアルロン酸産生促進剤
JP2004352628A (ja) * 2003-05-28 2004-12-16 Kuraray Co Ltd 皮膚外用剤
JP2006166807A (ja) * 2004-12-16 2006-06-29 Takafumi Ishikawa 健康美容食品
JP2010229111A (ja) * 2009-03-27 2010-10-14 Shiseido Co Ltd ヒアルロン酸産生促進剤
JP2010265251A (ja) * 2009-05-13 2010-11-25 Bhn Kk 血流促進改善剤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4700313B2 (ja) * 2004-09-27 2011-06-15 サントリーホールディングス株式会社 プロアントシアニジン及びスフィンゴ脂質を含む組成物
JP5016535B2 (ja) * 2008-03-27 2012-09-05 株式会社 資生堂 抗老化用食品補助剤および抗老化剤
JP4420357B1 (ja) * 2009-03-24 2010-02-24 株式会社資生堂 ヒアルロン酸産生促進剤
JP4413272B1 (ja) * 2009-04-06 2010-02-10 株式会社資生堂 ヒアルロン酸産生促進剤
JP2011195504A (ja) * 2010-03-19 2011-10-06 Shiseido Co Ltd ヒアルロン酸産生促進剤、抗老化剤およびしわ改善剤
JP2012067082A (ja) * 2010-08-23 2012-04-05 Yuki Yamashita 経口組成物
JP2012056919A (ja) * 2010-09-13 2012-03-22 Shiseido Co Ltd ヒアルロン酸産生促進剤
JP2012121871A (ja) * 2010-12-10 2012-06-28 Shiseido Co Ltd 皮膚バリア機能改善剤

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07206675A (ja) * 1993-10-11 1995-08-08 Asta Medica Ag 血行変化の治療薬
JP2004123637A (ja) * 2002-10-04 2004-04-22 Ichimaru Pharcos Co Ltd ヒアルロン酸産生促進剤
JP2004352628A (ja) * 2003-05-28 2004-12-16 Kuraray Co Ltd 皮膚外用剤
JP2006166807A (ja) * 2004-12-16 2006-06-29 Takafumi Ishikawa 健康美容食品
JP2010229111A (ja) * 2009-03-27 2010-10-14 Shiseido Co Ltd ヒアルロン酸産生促進剤
JP2010265251A (ja) * 2009-05-13 2010-11-25 Bhn Kk 血流促進改善剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KOHEI HASEBE ET AL.: "Natural crude extracts as suppressor of skin-darkness and dullness", FRAGRANCE J., vol. 24, no. 2, 1996, pages 41 - 46 *
TSUTOMU NOZAKI: "Development trend of inner cosmetic material", FOOD PROCESSING AND INGREDIENTS, vol. 44, no. 7, 2009, pages 16 - 18 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10226422B2 (en) 2013-01-23 2019-03-12 Bottled Science Limited Skin enhancing beverage composition

Also Published As

Publication number Publication date
CN103501800B (zh) 2017-01-18
CN103501800A (zh) 2014-01-08
KR20140027947A (ko) 2014-03-07
KR101840508B1 (ko) 2018-03-20
TWI436774B (zh) 2014-05-11
JP6205616B2 (ja) 2017-10-04
CN107050438A (zh) 2017-08-18
PH12013502215A1 (en) 2013-12-16
JP2012236826A (ja) 2012-12-06
TW201300136A (zh) 2013-01-01

Similar Documents

Publication Publication Date Title
JP6205616B2 (ja) 美肌促進剤及びその利用
JP5479891B2 (ja) 新規ローヤルゼリー分画物とその製造方法並びに用途
US20100323044A1 (en) Abnormal protein removing method
JP4470212B2 (ja) 皮膚改善剤
WO2007037060A1 (fr) Composition pour accélérer la production de collagène de type i
JP2008280271A (ja) 皮膚光老化予防剤
JP5571280B2 (ja) 皮脂産生促進剤
JP2008280311A (ja) 高脂血症予防・治療剤
KR102525595B1 (ko) 피쉬 콜라겐 함유 건강 식품 조성물
JP2008099562A (ja) 美肌用経口組成物
JP2023118853A (ja) 抗老化用組成物、抗老化用皮膚化粧料および抗老化用飲食品
JP2008308505A (ja) 異常蛋白質除去用組成物
JP2008280310A (ja) テストステロン生成及び代謝促進剤
JP2004107245A (ja) 目元のくすみ・クマ・むくみ改善用キット
JP2008239505A (ja) 神経芽細胞増殖促進剤及び神経突起伸展剤
JP2012067082A (ja) 経口組成物
JP2012246244A (ja) 毛細血管退行抑制剤
JP2004331543A (ja) 線維芽細胞増殖促進剤及び皮膚化粧料並びに美容用飲食物
JP2004107242A (ja) 乾燥肌改善用キット
JP2007016004A (ja) 繊維芽細胞増殖促進剤
JP2008031136A (ja) ヒアルロン酸産生増強剤
HK1242623A1 (en) Beautiful-skin-promoting agent and use thereof
JP5245061B2 (ja) 経口用老化防止剤及び美容方法
HK1193744B (en) Beautiful-skin-promoting agent and use thereof
HK1193744A (en) Beautiful-skin-promoting agent and use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12775997

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 20137026500

Country of ref document: KR

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12775997

Country of ref document: EP

Kind code of ref document: A1